Andrew Cournoyer, RPh, MBA

Pharma Insights

De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions

12/05/2022

Jacquelyn W Chou, MPP, MPL

Alexandria Portelli, MPH

Andrew Cournoyer, RPh, MBA

The authors discuss how a strategic HEOR evidence-generation plan that comprehensively communicates the value of a new drug helps to ensure that patients have access to innovative drugs and health care stakeholders have access to data to...

The authors discuss how a...

12/05/2022

Journal of Clinical Pathways

Pharma Insights

Bending the Health Care Cost Curve and Changing the Drug Cost Paradigm in 2021 and Beyond

04/22/2021

Elizabeth Oyekan, PharmD, FCSHP, CPHQ

Andrew Cournoyer, RPh, MBA

The continued rise in health care spending continues to have a profound effect on the US economy and health care payers. The three complex drivers contributing to these increases include hospital, outpatient, and...

The...

04/22/2021

Journal of Clinical Pathways